You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 9, 2024

Sarecycline hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sarecycline hydrochloride and what is the scope of patent protection?

Sarecycline hydrochloride is the generic ingredient in one branded drug marketed by Almirall and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sarecycline hydrochloride has seventy-one patent family members in twenty countries.

One supplier is listed for this compound.

Summary for sarecycline hydrochloride
International Patents:71
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 42
Clinical Trials: 6
Patent Applications: 12
What excipients (inactive ingredients) are in sarecycline hydrochloride?sarecycline hydrochloride excipients list
DailyMed Link:sarecycline hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for sarecycline hydrochloride
Generic Entry Date for sarecycline hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sarecycline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Beijing Tiantan HospitalPhase 2
NeuroDawn Pharmaceutical Co., Ltd.Phase 2
Derm Research, PLLCPhase 4

See all sarecycline hydrochloride clinical trials

Pharmacology for sarecycline hydrochloride
Drug ClassTetracycline-class Drug
Mechanism of ActionP-Glycoprotein Inhibitors
Anatomical Therapeutic Chemical (ATC) Classes for sarecycline hydrochloride

US Patents and Regulatory Information for sarecycline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for sarecycline hydrochloride

Country Patent Number Title Estimated Expiration
South Korea 20090098986 박테리아, 바이러스 및 기생충 감염의 치료를 위한 테트라시클린 유도체 (TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS) ⤷  Try a Trial
Slovenia 2120963 ⤷  Try a Trial
European Patent Office 2109602 DERIVÉS DE LA TETRACYCLINE POUR LE TRAITEMENT DE INFECTIONS BACTERIELLES, VIRALES ET PARASITIQUES (TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.